Alzheimer’s
Neuroptix Raises $18.5 Million in Successful B Round
Neuroptix Corporation has successfully raised a total of $18.5 million in its Series B funding round, as the company advances its diagnostic Alzheimer’s test toward clinical trials.
The investment, led by Inventages, will advance continued development of the Neuroptix Sapphire diagnostic platform and related technologies. The Neuroptix Sapphire system consists of a non-contact optical device combined [...]
Failed Drug in Alzheimers and Prostate Cancer Gets Licensed in Europe
Myriad Genetics announced today that it has licensed the European commercialization rights of its phase 3, beta-amyloid reducer (FLURIZAN) to H. Lundbeck A/S today for $100M upfront and $250M in developmental milestones. In addition, they managed to squeeze Lundbeck escalating, 20-39% royalties on sales. One hundred million upfront for the rights to commercialize in [...]
Astellas Pharma and CoMentis Sign $760M Alzheimer’s Deal
Astellas Pharma, Inc. and CoMentis, Inc. announced today that the companies have entered into an agreement to develop products from CoMentis’ beta-secretase inhibitor program, including the recently initiated, phase 2, lead candidate compound CTS-21166, an oral beta-secretase inhibitor for the treatment of Alzheimer’s disease. The agreement also includes a research collaboration to develop additional beta-secretase [...]
Recent Comments